Investigating liver health in adults with Turner Syndrome
Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants in an Observational Study
This study looks at liver health in adults with Turner Syndrome to see how common liver problems are and what might cause them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06794190 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of liver alterations in adult patients with Turner Syndrome (TS) by analyzing laboratory and imaging data. It will involve a retrospective cohort of patients monitored at the Endocrinology and Diabetes Prevention and Care unit in Bologna. The study will collect detailed medical histories, anthropometric measurements, and laboratory investigations to identify potential etiopathogenetic factors associated with hepatopathy in TS patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older with a confirmed diagnosis of Turner Syndrome.
Not a fit: Patients currently undergoing treatment with drugs that significantly alter liver enzymes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of liver health in Turner Syndrome, leading to better management and treatment strategies for affected patients.
How similar studies have performed: While there may be limited studies specifically focusing on hepatopathy in Turner Syndrome, similar observational studies have provided valuable insights into the health complications associated with genetic syndromes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Turner syndrome made by karyotype analysis on peripheral blood. * Age 18 years or older * Written informed consent obtained Exclusion Criteria: * TS patients on therapy with drugs responsible for significant liver enzyme alterations (liver function alteration, LFA).
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Alessandra Gambineri, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Alessandra Gambineri, MD
- Email: alessandra.gambineri@aosp.bo.it
- Phone: +390512144628
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.